ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


SEARCH JOBS

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. Our Company’s lead product candidate is HEPLISAV ™, an Investigational adult hepatitis B vaccine designed to
enhance protection more rapidly and with fewer doses than current licensed vaccines.

Clinical-Sage Pipeline

Our Clinical-stage pipeline includes 3 product candidates for the prevention and treatment of infectious diseases.

• Phase 3 HEPLISAV ™ Hepatitis B Vaccine
• Autoimmunity/Inflammation—Glaxo Smith Kline (GSK)
• Asthma/COPD—Astra Zenica

Focused on Infectious Disease

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product
candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.

Leading Partners

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca. Our funding
agreements support our commitment discover and develop TLR-based products to address serious medical diseases.

Integrated European Subsidiary

Rhein Biotech. Our European subsidiary, manufactures hepatitis B surface antigen for our lead product HEPLISAV ™ Hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.

Join an organization with cutting edge science and an experienced team dedicated towards discovering and developing products to prevent and treat infectious diseases. We offer a work environment that fosters learning, respect, open communication, integration, collaboration, and team orientation. Our employees work hard together, have fun, and share in the Company’s accomplishments.


 Key Statistics


Email: contact@dynavax.com
Ownership: Public

Web Site: Dynavax Technologies Corporation
Employees:
Symbol: DVAX
 









 Company News
Dynavax Technologies Corporation (DVAX) Announces Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B™ 11/10/2014 9:05:32 AM
Dynavax Technologies Corporation (DVAX) Announces One-for-Ten Reverse Stock Split 11/10/2014 8:51:31 AM
Dynavax Technologies Corporation (DVAX) Reports Third Quarter 2014 Financial Results 11/6/2014 1:42:45 PM
Dynavax Technologies Corporation (DVAX) Reports Third Quarter 2014 Financial Results 11/5/2014 1:55:06 PM
Dynavax Technologies Corporation (DVAX) Initiates Phase 1/2 Study Of TLR-9 Agonist Immunotherapy In B-Cell Lymphoma 10/13/2014 10:28:42 AM
Dynavax Technologies Corporation (DVAX) Announces Resignation Of Dino Dina From Board Of Directors 10/8/2014 9:35:17 AM
Dynavax Technologies Corporation (DVAX) Announces Resignation Of Dino Dina From Board of Directors 10/7/2014 2:39:03 PM
Dynavax Technologies Corporation (DVAX) Completes Enrollment Of Phase 3 Study Of HEPLISAV-B™ 9/22/2014 9:18:02 AM
Dynavax Technologies Corporation (DVAX) Reports Second Quarter 2014 Financial Results And Safety And Pharmacodynamic Results For Asthma And Lupus Drug Candidates 8/7/2014 8:42:53 AM
Dynavax Technologies Corporation (DVAX) To Present At The William Blair 2014 Growth Stock Conference 6/10/2014 10:26:19 AM
12345678910...